Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.

doi:10.5246/jcps.2020.04.027

中国药学(英文版) ›› 2020, Vol. 29 ›› Issue (4): 280-293.DOI: 10.5246/jcps.2020.04.027

Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.

Thananchanoke Rattanathada¹, Tullayakorn Plengsuriyakarn^1,2, Rathapon Asasujarit³, Anurak Cheoymang¹, Juntra Karbwang⁴, Kesara Na-Bangchang^1,2,5*

1. Graduate Program in Bioclinical Science, Chulabhorn International College of Medicine, Thammasat University, Phaholyothin Road, Khlong Luang, Pathum Thani12120, Thailand
2. Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University, Phaholyothin Road, Khlong Luang, Pathum Thani 12120, Thailand
3. Department of Pharmaceutical Sciences, Faculty of Pharmacy, Thammasat University, Pathumthani 12120, Thailand
4. Department of Clinical Product Development, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
5. Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathumthani 12120, Thailand

收稿日期:2019-12-11 修回日期:2020-01-04 出版日期:2020-04-30 发布日期:2020-02-15
通讯作者: Tel.: +66-25644440 ext 1803, E-mail: kesaratmu@yahoo.com
基金资助:
Financial support by National Research Council of Thailand (NRCT), Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma and Chulabhorn International College of Medicine (CICM), Thammasat University, Thailand.

Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.

Thananchanoke Rattanathada¹, Tullayakorn Plengsuriyakarn^1,2, Rathapon Asasujarit³, Anurak Cheoymang¹, Juntra Karbwang⁴, Kesara Na-Bangchang^1,2,5*

1. Graduate Program in Bioclinical Science, Chulabhorn International College of Medicine, Thammasat University, Phaholyothin Road, Khlong Luang, Pathum Thani12120, Thailand
2. Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University, Phaholyothin Road, Khlong Luang, Pathum Thani 12120, Thailand
3. Department of Pharmaceutical Sciences, Faculty of Pharmacy, Thammasat University, Pathumthani 12120, Thailand
4. Department of Clinical Product Development, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
5. Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathumthani 12120, Thailand

Received:2019-12-11 Revised:2020-01-04 Online:2020-04-30 Published:2020-02-15
Contact: Tel.: +66-25644440 ext 1803, E-mail: kesaratmu@yahoo.com
Supported by:
Financial support by National Research Council of Thailand (NRCT), Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma and Chulabhorn International College of Medicine (CICM), Thammasat University, Thailand.

摘要/Abstract

摘要：

Cholangiocarcinoma (CCA), the adenocarcinoma of the biliary duct, is commonly reported in Asia with the highest incidence in northeastern Thailand. Chemotherapy of this type of cancer is limited due to the lack of effective chemotherapeutic drugs. A series of previous studies support further research and development of Atractylodes lancea (Thunb) DC. (AL) as a potential candidate for the treatment of CCA as a crude ethanolic extract. In the present study, we aimed to develop an oral pharmaceutical formulation (capsule) of the standardized AL crude ethanolic extract for further clinical development in patients with CCA. Major steps included macroscopic and microscopic authentication of the AL rhizomes, preparation of standardized AL extract, preparation of oral pharmaceutical formulation (capsule) of the standardized AL extract, quantitative and qualitative analysis of the marker compound (atractylodin) in the formulated AL extract, evaluation of contaminations of heavy metals, pesticides residues, and microorganisms in the ground AL rhizomes and the formulated (capsule) powder of AL, physicochemical and pharmaceutical properties of the formulatedAL extract/capsule, and cytotoxicity evaluation of the formulated AL extract. Results of all evaluations confirmed satisfactory pharmaceutical properties of oral (capsule) formulation of the standardized AL extract.

关键词: Atractylodes lancea (Thunb) DC., Capsule formulation, Atractylodin, β-Eudesmol, Cholangiocarcinoma

Abstract:

Key words: Atractylodes lancea (Thunb) DC., Capsule formulation, Atractylodin, β-Eudesmol, Cholangiocarcinoma

中图分类号:

R943

Supporting:

Thananchanoke Rattanathada, Tullayakorn Plengsuriyakarn, Rathapon Asasujarit, Anurak Cheoymang, Juntra Karbwang, Kesara Na-Bangchang. Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.[J]. 中国药学(英文版), 2020, 29(4): 280-293.

参考文献

[1] Rerknimitr, R.; Angsuwatcharakon, P.; Ratanachuek, T.; Khor, C.J.; Ponnudurai, R.; Moon, J.H.; Seo, D.W.; Pantongrag-Brown, L.; Sangchan, A.; Pisespongsa, P.; Akaraviputh, T.; Reddy, N.D.; Maydeo, A.; Itoi, T.; Pausawasdi, N.; Punamiya, S.; Attasaranya, S.; Devereaux, B.; Ramchandani, M.; Goh, K.L. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J. Gastroenterol. Hepatol. 2013, 28, 593-607.

[2] Sripa, B.; Kaewkes, S.; Sithithaworn, P.; Mairiang, E.; Laha, T.; Smout, M.; Pairojkul, C.; Bhudhisawasdi, V.; Tesana, S.; Thinkamrop, B.; Bethony, J.M.; Loukas, A.; Brindley, P.J. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007, 4, e201.

[3] Ganeshan, D.; Moron, F.E.; Szklaruk, J. Extrahepatic biliary cancer: New staging classification. World J. Radiol. 2012, 4, 345-352.

[4] Na-Bangchang, K.; Plengsuriyakarn, T.; Karbwang, J. Research and development of Atractylodes lancea (thunb) DC. as a promising candidate for cholangiocarcinoma chemotherapeutics. Evid. Based Complement. Alternat. Med. 2017, 2017, 5929234.

[5] Na-Bangchang, K.; Karbwang, J. Traditional herbal medicine for the control of tropical diseases. Trop. Med. Health. 2014, 42, 3-13.

[6] Mahavorasirikul, W.; Viyanant, V.; Chaijaroenkul, W.; Itharat, A.; Na-Bangchang K. Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement. Altern. Med. 2010, 10, 55.

[7] Patel, T. Cholangiocarcinoma: controversies and challenges. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 189-200.

[8] Thongprasert, S.; Napapan, S.; Charoentum, C.; Moonprakan, S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann. Oncol. 2005, 16, 279-281.

[9] Ramírez-Merino, N.; Aix, S.P.; Cortés-Funes, H. Chemotherapy for cholangiocarcinoma: an update. World J. Gastrointest. Oncol. 2013, 5, 171-176.

[10] Ustundag, Y.; Bayraktar, Y. Cholangiocarcinoma: a compact review of the literature. World J. Gastroenterol. 2008, 14, 6458-6466.

[11] Wattanawongdon, W.; Hahnvajanawong, C.; Namwat, N.; Kanchanawat, S.; Boonmars, T.; Jearanaikoon, P.; Leelayuwat, C.; Techasen, A.; Seubwai, W. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Int. J. Oncol. 2015, 47, 398-410.

[12] Watanabe-Galloway, S.; Flom, N.; Xu, L.Y.; Duran, T.; Frerichs, L.; Kennedy, F.; Smith, C.B.; Jaiyeola, A.O. Cancer-related disparities and opportunities for intervention in Northern Plains American Indian communities. Public Health Rep. 2011, 126, 318-329.

[13] Choudhary, N.; Sekhon, B.S. An overview of advances in the standardization of herbal drug. J. Pharm. Educ. Res. 2011, 2, 55-70.

[14] Yousef, F.; Salame, R.; Hammad, T. Formulation and evaluation of herbal tablets and hard capsules containing Urtica dioica soft extract. Int. J. Pharm. Sci. Rev. Res. 2015, 32, 98-102.

[15] Monton, C.; Saingam, W.; Suksaeree, J.; Sakunpak, A. Formulation development and physical properties study of Thai traditional herbal tablets: Jit-Tra-Rom Recipie. Int. J. Pharm. Pharm. Sci. 2014, 6, 12-21.

[16] Singh, A.; Waldia, A. Formulation and evaluation of polyherbal capsules for antidiabetic activity. WJPPS. 2015, 4, 1796-1801.

[17] Plengsuriyakarn, T.; Thitapakorn, V.; Na-Bangchang, K.; Karbwang, J. Thai medicinal plants: Potential sources of anticholangiocarcinoma drugs. Int. J. Pharm. Pharmacol. 2013, 2, 68-82.

[18] Xiao, P.G. Modern Chinese Materia Medica. Beijing: Science Press. 2002.

[19] Koonrungsesomboon, N.; Na-Bangchang, K.; Karbwang, J. Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC. Asian Pac. J. Trop. Med. 2014, 7, 421-428.

[20] Chinese Pharmacopoeia CHN, the Pharmacopoeia of the People’s Republic of China 2015, http://wp.chp.org.cn/front/chpint/en/(accessed Dec. 1, 2015).

[21] Kitajima, J.; Kamoshita, A.; Ishikawa, T.; Takano, A.; Fukuda, T.; Isoda, S.; Ida, Y. Glycosides of Atractylodes lancea. Chem. Pharm. Bull. 2003, 51, 673-678.

[22] Takeda, O.; Miki, E.; Terabayashi, S.; Okada, M.; Lu, Y.; He, H.S.; He, S.A. A comparative study on essential oil components of wild and cultivated Atractylodes lancea and A. Chinensis. Planta Med. 1996, 62, 444-449.

[23] Kohjyouma, M.; Nakajima, S.; Namera, A.; Shimizu, R.; Mizukami, H.; Kohda, H. Random amplified polymorphic DNA analysis and variation of essential oil components of Atractylodes plants. Biol. Pharm. Bull. 1997, 20, 502-506.

[24] Li, N.; Deng, C.H.; Li, Y.; Ye, H.; Zhang, X.M. Gas chromatography-mass spectrometry following microwave distillation and headspace solid-phase microextraction for fast analysis of essential oil in dry traditional Chinese medicine. J. Chromatogr. A. 2006, 1133, 29-34.

[25] Chen, Y.M.; Chou, G.X.; Wang, Z.T. Determination of beta-eudesmol in rhizome of Atractylodes lancea by RP-HPLC. China J. Chin. Mater. Med. 2007, 32, 2265-2267.

[26] Ouyang, Z.; Yang, L.; Su, S.L.; Feng, X.; Wang, M. Fingerprint of volatile oil of Atractylodes lancea by GC-MS. Acta Pharm. Sin. 2007, 42, 968-972.

[27] Plengsuriyakarn, T.; Viyanant, V.; Eursitthichai, V.; Picha, P.; Kupradinun, P.; Itharat, A.; Na-Bangchang, K. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement. Altern. Med. 2012, 12, 23.

[28] Plengsuriyakarn, T.; Matsuda, N.; Karbwang, J.; Viyanant, V.; Hirayama, K.; Na-Bangchang, K. Anticancer activity of Atractylodes lancea (thunb.) DC in a hamster model and application of PET-CT for early detection and monitoring progression of cholangiocarcinoma. Asian Pac. J. Cancer Prev. 2015, 16, 6279-6284.

[29] Martviset, P.; Chaijaroenkul, W.; Muhamad, P.; Na-Bangchang, K. Bioactive constituents isolated from Atractylodes lancea (Thunb.) DC. rhizome exhibit synergistic effect against cholangiocarcinoma cell. J. Exp. Pharmacol. 2018, 10, 59-64.

[30] Tunsirikongkon, A.; Kraisit, P.; Seubsasana, S.; Itharat, A.; Sarisuta, N. Formulation Development of Herbal Capsule containing Oleoresin of Zingiber officinale Extract. Int. J. Pharm. Pharm. Sci. 2013, 5, 439-445.

[31] Jhade, D.; Ahirwar, D.; Jain, R.; Sharma, N.; Gupta, S. Pharmacognostic standardization, physico- and phyto-chemical evaluation of Amaranthus spinosus linn. Root. J. Young Pharm. 2011, 3, 221-225.

[32] Borhade, P.S.; Deshmukh, T.A.; Patil, V.R.; Khandelwal, K.R. Pharmacognostic and Phytochemical Investigations of Plumbago zeylanica Linn. root. J. Pharmacogn. Phytochem. 2014, 2, 83-88.

[33] U.S. Department of Health and Human Services F, and Drug Administration aCfDEa, (CDER) R, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteer, Guidance for Industry 2005.

[34] Verma, S.C.; Jain, C.L.; Rani, R.; Pant, P.; Singh, R.; Padhi, M.M.; Devalla, R.B. Simple and rapid method for identification of Curcuma longa rhizomes by physicochemical and HPTLC fingerprint analysis. Chem. Sci. Trans. 2012, 1, 709-715.

[35] Atractylodis Rhizoma HK, Hong Kong Chinese Materia Medica Standards 2012.

[36] Thai Herbal Pharmacopoeia THA, Department of Medical Science, Ministry of Public Health 2017.

[37] British Pharmacopoeia UK, British Pharmacopoeia 2018.

[38] Convention TUSP, U.S. Pharmacopeia 41, National Formulary 362018.

[39] Rane Rajashree, G.D.; Sushma, P.; Kanchan, I. Formulations as Herbal Medicines and Nutraceuticals. Res. J. Pharmaceutical. Sci. 2012, 1, 10-15.

[40] USP Controlled Room Temperature Range Expansion 2014.

[41] Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983, 65, 55-63.

[42] Bhatt, D.; Jethva, K.; Patel, S.; Zaveri, M. Development and standardization of Polyherbal formulation for the management of breast cancer. Int. J. Pharm. Sci. Res. 2017, 2. 24-28.

[43] Hunt, D.G.; Chandler, C.; Ulrich, D.A.; Poska, R.; Montero, A. USP Controlled Room Temperature Range Expansion. Pharmacopeial. Forum. 2013, 39, 1-5.

[44] Zhu, S.D.; Peng, H.S.; Guo, L.P.; Xu, T.R.; Zhang, Y.; Chen, M.L.; Hao, Q.X.; Kang, L.P.; Huang, L.Q. Regionalization of Chinese Material Medical Quality Based on Maximum Entropy Model: A case study of Atractylodes lancea. Sci. Rep. 2017, 7, 42417.

Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.

Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb) DC.

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛钧升, 王思媛, 郝方然, 田秀云, 苏红, 杨亮, 安启明, 郝纯毅, 周田彦. 多巴胺增强舒尼替尼治疗胰腺癌的药效[J]. 中国药学(英文版), 2020, 29(10): 689-700.
[2]	李承群, 牛霞, 牟家慧, 王晓梅, 苏瑾, 李桂玲. APT011缓释微球的制备及体外评价[J]. 中国药学(英文版), 2020, 29(8): 554-563.
[3]	张金, 林玮玮, 吴委, 郭仙忠, 黄品芳, 林新华, 焦正, 王长连. 中国老年患者万古霉素群体药动学及个体化给药应用研究[J]. 中国药学(英文版), 2020, 29(4): 260-271.
[4]	刘晓昕, 覃小雅, 李子圆, 范田园. 掺杂型超顺磁性氧化铁纳米簇的微波辅助制备及体外表征[J]. 中国药学(英文版), 2020, 29(3): 153-160.
[5]	王圣鑫, 闫向丽, 郑昊圳, 余健烨, 余爱明, 沈晓, 王利胜. 微透析技术结合液质联用的不同剂量黄芪的补阳还五汤在脑缺血损伤大鼠脑药动学研究[J]. 中国药学(英文版), 2020, 29(2): 90-101.
[6]	王雪玲, 梁艳琴, 张元, 何冰, 代文兵, 张华, 王学清, 张强. cRGD-DOX自组装纳米粒与贝伐珠单抗联合治疗乳腺癌[J]. 中国药学(英文版), 2019, 28(9): 627-640.
[7]	沈新宇, 王星辰, 顾彩虹, 严峰, 潘博, 高利增, 颜丙春, 刘岐, 胡荣. 较人参皂苷Rg3生物高效的新型制剂-竹节参片研究[J]. 中国药学(英文版), 2019, 28(9): 650-664.
[8]	靳尧, 刘琦, 周楚杭, 韩诗迪, 周远航, 胡新平, 王乐淇, 刘艳. 提高难溶药物小肠吸收的靶向寡肽转运体PepT1的聚合物胶束的制备与表征[J]. 中国药学(英文版), 2019, 28(8): 561-570.
[9]	王佳星, 王雨, 牟家慧, 魏潇萌, 殷梦雅, 刘雅婕, 李佳佳, 李馨儒. 脂质体对细菌外膜囊泡的修饰及其体外评价[J]. 中国药学(英文版), 2019, 28(8): 571-578.
[10]	沈琪, 王梅, 唐小慧, 木巴拉克.伊明江. 沙棘籽油纳米乳的制备及经皮渗透的可视化分析研究[J]. 中国药学(英文版), 2019, 28(8): 579-594.
[11]	杜祎甜, 张泸, 詹颖, 柴新宇, 李锴森, 齐宪荣. 制备干扰素脂质体使小胶质细胞维持M1表型[J]. 中国药学(英文版), 2019, 28(7): 476-483.
[12]	邓博, 崔巍, 马爽, 刘晓娜, 张展, 闫百艺, 陈坤, 谢英. RVGP修饰脑靶向脂质体合理构建的分子基础[J]. 中国药学(英文版), 2019, 28(7): 484-501.
[13]	郝艳丽, 钟婷, 杜若, 张华, 刘碧林, 张烜. 包载共轭亚油酸-紫杉醇的iRGD修饰的含溶血磷脂的温敏脂质体的细胞摄取和抗肿瘤药效[J]. 中国药学(英文版), 2019, 28(2): 121-133.
[14]	程士轩, 马迎聪, 刘瑜洁, 庞宁, 李骥, 沙勐, 任汝通, Nuramatjan Ablat, 曹静, 孙懿, 蒲小平, 叶敏, 齐宪荣. 红花抗帕金森病有效成分滴丸的制备和表征[J]. 中国药学(英文版), 2019, 28(1): 27-39.
[15]	彭光华, 张文茜, 宋茂远, 殷梦雅, 王佳星, 李佳佳, 刘雅婕, 张媛媛, 李馨儒, 李桂玲. 作为新型具有抗细菌生物膜活性的两亲性材料—鼠李糖苷的结构与活性之间的关系研究[J]. 中国药学(英文版), 2018, 27(12): 817-823.